ClinicalTrials.gg
CompletedNCT02824874Updated Jul 11, 2016

CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)

A Phase 1 interventional study of Duvie Tab. 0.5mg and Duvie Tab. 0.5mg + Januvia Tab. 100mg in Diabetes Mellitus, Type II, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-11.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.

Enrollment
23rd of 23
20 · median 41
Started
2016
with 1 other
Phase 1
14 of 23
none open now
Registered
11th of 23
by date
Lead sponsor
20 of 23
Chong Kun Dang Pharmaceutical

Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 2 that started in 2016, is one of 14 in phase 1, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

About lobeglitazone

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.

Read the detailed description

To healthy male subjects of twenty(20), following treatments are administered dosing in each period and wash-out period is a minimum of 10 days.

03

Conditions studied

  • Diabetes Mellitus, Type II
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A healthy male whose age is over 19 years old when visiting for initial screening test
  2. (BMI) between 17.5\~30.5 kg/m\^2 and the body weight must be over 55kg (Body mass index (BMI) = weight (kg) / height (m)\^2)
  3. A male with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area
  4. Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the (ECG), and etc.
  5. The participants must be volunteered and sign in an document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
  6. The participants must have an ability and willingness to participate throughout the entire trials

Exclusion criteria

Exclusion Criteria:

  1. A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous, or allergic(except subclinical seasonal allergies that is not treated at injecion) desease.
  2. Who had a gistory of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy)
  3. Who had following results after examination

    a. or AST > twice higher than normal value

  4. Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%) (125 mL) = 12g)
  5. Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial.
  6. Whose blood pressure ≤ 100 or ≥150(systolic blood pressure) or \< 60 or ≥ 100(diastolic blood pressure)
  7. Who had a medical history of alcohol and drug abuses.
  8. Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion) in 30 days before the first taking of clinical testing durg.
  9. WHo smokes more than 20 eigarettes per day.
  10. Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very first clinical testing drug.
  11. Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or donations in 1 month before the first taking to clinical testing drugs.
  12. Who has a potent to increase a danger by participating in the clinical trials or sho can interrupt interpretin test results by having serious or chronic medical and mental status or having issues in results of the screening examination.
  13. Who has a histroy of an extreme sensitivity of drugs that contain Rosiglitazone or dugs that have similar effect a Rosiglitazone(Pioglitazone), or drugs that contain the ingredients of Sitagliptin or thiazolidinediones drugs.
  14. Who has a serious heart failure or a congestive heart failure that must be drug-treated
  15. A patient with hepatopathy.
  16. A patient with wevere nephropathy.
  17. Who has diabetic ketoacidosis or a diaetic coma, or type 1 diabetes, or has history of acute metablic acidosis or ketoacidosis.
  18. A patient with serious infectious disease or severe injuries before and after a surgery.
  19. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.
  20. Test subjects who is not willing or unable to comply with guidelines described in this protocol.
  21. A person who is not determined unsuitable to participate in this test by the researchers.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Group 1(Treatment A/Treatment B)

    Period 1: Treatment A(Duvie Tab. 0.5mg)\*1T/day for 5 days, QD, PO Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)\*1T/day for 5 dyas, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.

    Drug: Duvie Tab. 0.5mg · Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg

  • Experimental
    Group 2(Treatment B/Treatment A)

    Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)\*1T/day for 5 dyas, QD, PO Period 2: Treatment A(Duvie Tab. 0.5mg)\*1T/day for 5 days, QD, PO Each treatment period was separated by a washout period of at least 10 dyas.

    Drug: Duvie Tab. 0.5mg · Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg

Interventions

  • Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO

    Also known as: Lobeglitazone 0.5mg

  • DrugDuvie Tab. 0.5mg + Januvia Tab. 100mg

    Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO

    Also known as: Lobeglitazone 0.5mg + Sitagliptin 100mg

06

What researchers measure

Primary outcomes

  1. AUCτ of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  2. Css,max of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

Secondary outcomes

  1. Css,min of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  2. Css,av of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  3. Tss,max of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  4. t1/2 of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  5. CLss/F of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  6. Vdss/F of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  7. fluctuation[(Css,max-Css,min)/Css,av] of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

  8. swing[(Css,max-Css,min)/Css,min] of Lobeglitazone

    Time frame: 1Day 0h, 3Day 0h, 4Day 0h, 5Day 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju-si, Korea, Republic of
08

References and documents

Publications

  • Moon SJ, Yu KS, Kim MG. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. Clin Ther. 2020 Jun;42(6):1047-1057. doi: 10.1016/j.clinthera.2020.04.005. Epub 2020 Apr 30. PubMed 32362346 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2016
First posted
Jul 7, 2016
Start
Apr 2016
Primary completionActual
Apr 2016
CompletionActual
May 2016
Last update
Jul 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02824874
Responsible party
Sponsor
First posted
Jul 7, 2016
Start date
Apr 2016
Primary completion
Apr 2016
Completion
May 2016
Last update
Jul 11, 2016

Study contacts

Min-Gul Kim, MD,PhD
study director · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion